Xiying Li

Xiying Li

Auto-generated profile, based on publicly available information

Xiying Li

Department of Blood Transfusion, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
RLRongrong Luo
Rongrong Luo
XLXiying Li
Xiying Li
RGRuyun Gao
Ruyun Gao
MYMengwei Yang
Mengwei Yang
JCJuan Cai
Juan Cai
XHXiaohong Han
Xiaohong Han
Autoantibodies hold promise for diagnosing lung cancer. However, their effectiveness in early-stage detection needs improvement. In this study, we investigated novel IgG and IgM autoantibodies for detecting early-stage lung adenocarcinoma (Early-LUAD) by employing a multi-step approach, including Human Proteome Microarray (HuProtTM) discovery, focused microarray verification, and ELISA validation, on 1246 individuals consisting of 634 patients with Early-LUAD (stage 0–I), 280 patients with benign lung disease (BLD), and 332 normal healthy controls (NHCs). HuProtTM selected 417 IgG/IgM candidates, and focused microarray further verified 55 significantly elevated IgG/IgM autoantibodies targeting 32 tumor-associated antigens in Early-LUAD compared to BLD/NHC/BLD+NHC. A novel panel of 10 autoantibodies (ELAVL4-IgM, GDA-IgM, GIMAP4-IgM, GIMAP4-IgG, MGMT-IgM, UCHL1-IgM, DCTPP1-IgM, KCMF1-IgM, UCHL1-IgG, and WWP2-IgM) demonstrated a sensitivity of 70.5% and a specificity of 77.0% or 80.0% for distinguishing Early-LUAD from BLD or NHC in ELISA validation. Positive predictive values for distinguishing Early-LUAD from BLD with nodules ≤ 8 mm, 9–20 mm, and > 20 mm significantly increased from 47.27%, 52.00%, and 62.90% [low-dose computed tomography (LDCT) alone] to 79.17%, 71.13%, and 87.88% (10-autoantibody panel combined with LDCT), respectively. The combined risk score (CRS), based on the 10-autoantibody panel, sex, and imaging maximum diameter, effectively stratified the risk for Early-LUAD. Individuals with 10 ≤ CRS ≤ 25 and CRS > 25 indicated a higher risk of Early-LUAD compared to the reference (CRS < 10), with adjusted odds ratios of 5.28 [95% confidence interval (CI): 3.18–8.76] and 9.05 (95% CI: 5.40–15.15), respectively. This novel panel of IgG and IgM autoantibodies offers a complementary approach to LDCT in distinguishing Early-LUAD from benign nodules.

1 March 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
RLRongrong Luo
Rongrong Luo
PZPei Zhong
Pei Zhong
XLXiying Li
Xiying Li
JCJuan Cai
Juan Cai
YTYimin Tao
Yimin Tao
XHXiaohong Han
Xiaohong Han
Background: Early diagnosis is critical to lung adenocarcinoma patients’ survival but faces inadequacies in convenient early detection. Methods: We applied a comprehensive microarray of 130,000 peptides to detect “autoantibody signature” that is autoantibodies binding to mimotopes for early detection of stage 0–I LUAD. Plasma samples were collected from 147 early-stage lung adenocarcinoma (Early-LUAD), 108 benign lung disease (BLD), and 122 normal healthy controls (NHC). Clinical characteristics, low-dose CT (LDCT), and laboratory tests were incorporated into correlation analysis. Results: We identified 143 and 133 autoantibody signatures, distinguishing Early-LUAD from NHC/BLD in the discovery cohort. Autoantibody signatures significantly correlated with age, stage, tumor size, basophil count, and IgM level (P < 0.05). The random forest models based on differential autoantibody signatures displayed AUC of 0.92 and 0.87 to discern Early-LUAD from NHC/BLD in the validation cohort, respectively. Compared with LDCT, combining autoantibody signature and LDCT improved the positive predictive value from 50% to 78.33% (P = 0.049). In addition, autoantibody signatures displayed higher sensitivity of 72.4% to 81.0% compared with the combinational tumor markers (cyfra21.1, NSE, SCC, ProGRP) with a sensitivity of 22.4% (P = 0.000). Proteins matched by differential peptides were enriched in cancer-related PI3K/Akt, MAPK, and Wnt pathways. Overlaps between matched epitopes and autoantibody signatures illustrated the underlying engagement of autoantibodies in immune recognition. Conclusions: Collectively, autoantibody signatures identified by a high-throughput peptide microarray have the potential to detect Early-LUAD, which could assist LDCT to better diagnose Early-LUAD. Impact: Novel sensitive autoantibody signatures can adjuvant LDCT to better diagnose LUAD at very early stage.

1 January 2023 in Clinical Laboratory
Verified
Journal Article
Closed access
WFWeiwei Fang
Weiwei Fang
CPCHENG PANG
CHENG PANG
FZFanguo Zhang
Fanguo Zhang
HZHaipo Zhang
Haipo Zhang
TPTao Peng
Tao Peng
XLXiying Li
Xiying Li
Red blood cell (RBC) transfusion therapy has greatly reduced mortality and morbidity in multiply transfused patients with oncological malignancies. The aim of this study was to underline the necessity of introducing a policy for extended RBC phenotyping of these patients and for the issuing of antigen-matched blood (at least for E antigen). Multivariate logistic regression analysis was used to evaluate the associations of age, gender, transfusion history, and various malignancies with the development of red cell alloimmunization. Given the results of antibody identification, we finally obtained 732 cases to be analyzed, designating them as the p group. The respiratory system (231/732; 31.6%), digestive system (273/732; 37.3%), and female reproductive system (127/732; 17.3%) had the three highest alloimmunization rates in the p group. We screened 81 cases from the p group for which antibody screening in our laboratory had historically yielded negative results. Among the 81 cases with antibody seroconversion, anti-E was the most frequently observed antibody (37%). The results related to multivariate logistic regression analysis of the Rh group indicate that, in contrast to the other variates, transfusion confers a strongly increased risk of Rh blood system-related red cell alloimmunization. To reduce alloimmunization in tumor patients, it will be essential to introduce a policy for extended RBC phenotyping of high-risk patients and for the issuing of antigen-matched blood (at least for E antigen).

26 November 2025
Verified
Other
Open access
RLRongrong Luo
Rongrong Luo
PZPei Zhong
Pei Zhong
XLXiying Li
Xiying Li
JCJuan Cai
Juan Cai
YTYimin Tao
Yimin Tao
XHXiaohong Han
Xiaohong Han
Reproducibility of peptides microarray. a, Heatmap of spearman correlation of 47 samples tested with 3 technical repeats within one batch. b. Heatmap of spearman correlation of 6 samples repeatedly tested across 3 batches.

4 April 2023
Verified
Other
Open access
RLRongrong Luo
Rongrong Luo
PZPei Zhong
Pei Zhong
XLXiying Li
Xiying Li
JCJuan Cai
Juan Cai
YTYimin Tao
Yimin Tao
XHXiaohong Han
Xiaohong Han
Figure S3. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus NHC. Each boxplot represents an individual peptide signature in the two sample sets.

4 April 2023
Verified
Other
Open access
RLRongrong Luo
Rongrong Luo
PZPei Zhong
Pei Zhong
XLXiying Li
Xiying Li
JCJuan Cai
Juan Cai
YTYimin Tao
Yimin Tao
XHXiaohong Han
Xiaohong Han
Figure S5. Correlation between differential autoantibody signatures from Early-LUAD versus BLD and blood routine test. Some of the 143 differential autoantibody signatures positively correlated with RDW.CV.